Alkermes Plc - Company Profile
Powered by 
All the sales intelligence you need on Alkermes Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Alkermes Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Alkermes Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on research, development, and commercialization of medicines for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, narcolepsy, and neurological disorders. The company’s proprietary products include Aristada and Aristada Initio, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It grants licenses under its proprietary technologies to enable third parties to develop, commercialize, and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors, and pharmacies. The company has global operations. Alkermes is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
Connaught House, 1 Burlington Road, Dublin 4, D04C5Y6
Website
www.alkermes.com
Telephone
353 1 7728000
No of Employees
2,050
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALKS (NASD)
Revenue (2024)
$1.5B
-5.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-34.2%
(2024 vs 2023)
Market Cap*
$8.6B
Net Profit Margin (2024)
XYZ
-30.6%
(2024 vs 2023)
* As of and is in US$
Alkermes Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed Products | Alkermes |
| Aristada – Schizophrenia | Aristada |
| Aristada Initio - Schizophrenia | Vivitrol |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In February, the company acquired Avadel Pharmaceuticals plc, a biopharmaceutical company. |
| 2025 | Others | In April, the company announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia. |
| 2024 | Divestiture | In May, the company completed the sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. |
Competitor Comparison
| Key Parameters | Alkermes Plc | Eli Lilly and Co | AbbVie Inc | Novartis AG | Sanofi |
|---|---|---|---|---|---|
| Headquarters | Ireland | United States of America | United States of America | Switzerland | France |
| City | Dublin | Indianapolis | North Chicago | Basel | Paris |
| State/Province | Dublin | Indiana | Illinois | Basel-Stadt | Ile-de-France |
| No. of Employees | 2,050 | 50,605 | 57,000 | 75,267 | 76,493 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard F. Pops | Chairman; Chief Executive Officer | Executive Board | 2011 | 64 |
| Joshua Reed | Chief Financial Officer | Senior Management | 2025 | 53 |
| Blair C. Jackson | Chief Risk Officer; Chief Operating Officer; Executive Vice President | Senior Management | 2024 | 53 |
| Tom Skoff | Chief Information Officer; Senior Vice President | Senior Management | - | - |
| David J. Gaffin | Executive Vice President; Secretary; Chief Legal Officer; Chief Compliance Officer | Senior Management | 2022 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer